Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines

Acta Neurologica Scandinavica

Volumn 122, Issue 4, 2010, Pages 237-243

  Vogelgesang, A ^a   Rosenberg, S ^a   Skrzipek, S ^a   Broker B M ^a   Dressel, A ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

CD4+ T cells; CD8+ T cells; interleukin 17; interleukin 4; interleukin 5; lymphocytes; mitoxantrone; multiple sclerosis; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MITOXANTRONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ADULT; AGED; CELL PROLIFERATION; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS; TH2 CELLS; TREATMENT OUTCOME;

EID: 77956415062     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01295.x     Document Type: Article

References (30)

1. Rieckmann P, Toyka KV, Bassetti C et al. Escalating immunotherapy of multiple sclerosis - new aspects and practical application. J Neurol 2004 251 : 1329 1339.
2. Rep MH, Schrijver HM, Van Lopik T et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999 96 : 92 100.
3. Ozenci V, Kouwenhoven M, Huang YM, Kivisakk P, Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000 120 : 147 153.
4. Dayal AS, Jensen MA, Lledo A, Arnason BG. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995 45 : 2173 2177.
5. Furlan R, Bergami A, Lang R et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J Neuroimmunol 2000 111 : 86 92.
6. Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2007 13 : 459 470.
7. Uhm JH, Dooley NP, Stuve O et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 1999 46 : 319 324.
8. Stuve O, Dooley NP, Uhm JH et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996 40 : 853 863.
9. Dressel A, Mirowska-Guzel D, Gerlach C, Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol Scand 2007 116 : 164 168.
10. Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 1999 46 : 253 256.
11. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002 360 : 2018 2025.
12. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983 10 (Suppl. B 3 11.
13. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004 63 : S28 32.
14. Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006 63 : 1572 1578.
15. Fidler JM, Dejoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986 137 : 727 732.
16. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005 139 : 152 158.
17. Fidler JM, Dejoy SQ, Smith FR III., Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986 136 : 2747 2754.
18. Angelucci F, Batocchi AP, Caggiula M et al. In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. Neuroimmunomodulation 2006 13 : 76 81.
19. Neuhaus O, Wiendl H, Kieseier BC et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005 168 : 128 137.
20. Bielecki B, Mazurek A, Wolinski P, Glabinski A. Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. J Clin Immunol 2008 28 : 122 130.
21. Dressel A, Vogelgesang A, Brinkmeier H, Mader M, Weber F. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. J Neuroimmunol 2006 181 : 133 140.
22. Karandikar NJ, Crawford MP, Yan X et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 2002 109 : 641 649.
23. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007 204 : 1849 1861.
24. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006 354 : 942 955.
25. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008 14 : 337 342.
26. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immun 2007 8 : 913 919.
27. Crawford MP, Yan SX, Ortega SB et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004 103 : 4222 4231.
28. Karni A, Balashov K, Hancock WW et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004 146 : 189 198.
29. Hafler DA, Orav EJ, Gertz R, Stazzone L, Weiner HL. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991 32 : 149 158.
30. Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997 42 : 313 318.